Linked Data API

Show Search Form

Search Results

993365
star this property registered interest false more like this
star this property date less than 2018-10-22more like thismore than 2018-10-22
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
star this property hansard heading Haematological Cancer: Drugs more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government (1) how many drugs were available on the NHS for the treatment of blood cancer, and (2) how much the NHS spent on blood cancer drugs, in each of the past five years. more like this
star this property tabling member printed
Lord Mendelsohn remove filter
star this property uin HL10893 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2018-11-05more like thismore than 2018-11-05
unstar this property answer text <p>NHS England has advised that it is not possible to provide a comprehensive list of drugs that are available specifically for blood cancer or how much the National Health Service spends on blood cancer drugs as cancer drugs are often licenced for multiple different types of cancer.</p> more like this
star this property answering member printed Lord O'Shaughnessy more like this
star this property question first answered
less than 2018-11-05T14:29:39.827Zmore like thismore than 2018-11-05T14:29:39.827Z
star this property answering member
4545
star this property label Biography information for Lord O'Shaughnessy more like this
star this property tabling member
4286
unstar this property label Biography information for Lord Mendelsohn more like this
922991
star this property registered interest false more like this
star this property date less than 2018-06-12more like thismore than 2018-06-12
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
star this property hansard heading Leukaemia: Ibrutinib more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government (1) what evidence NHS England considered, (2) which clinicians it consulted, and (3) which patient groups it consulted when deciding that ibrutinib should not be prescribed to people with chronic lymphocytic leukaemia who have been in remission for more than three years. more like this
star this property tabling member printed
Lord Mendelsohn remove filter
star this property uin HL8564 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2018-06-26more like thismore than 2018-06-26
unstar this property answer text <p>NHS England has advised that it develops treatment criteria for cancer and other high cost drugs to support implementation of National Institute for Health and Care Excellence (NICE) guidance and to ensure approved treatments are available as intended, with access funded consistently across the country. These criteria are developed by relevant expert clinical advisers, drawn from NHS England’s 42 Clinical Reference Groups (CRGs). These CRGs have been established to support clinical commissioning across the entire specialised commissioning portfolio.</p><p>In the case of NICE Technology Appraisal TA429 for ibrutinib in previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation, NICE issued the following statement on 8 June 2018:</p><p><strong> </strong>“Given the evidence that was considered by the NICE appraisal committee, we consider it reasonable for the guidance to be read as referring to those patients considered unsuitable for retreatment. Because unsuitability for retreatment is not defined in the guidance, we consider it appropriate for NHS England, as the commissioner, to take clinical advice in order to do so.”</p><p>NHS England took clinical advice in setting the specific treatment criteria linked to this appraisal and we are advised that the criteria were derived from the main study that had underpinned the NICE guidance and are consistent with guidance issued by the European Society for Medical Oncology last updated in June 2017. Between January 2017 and May 2018, nearly 1,000 patients were registered to receive treatment with ibrutinib in this indication. This is in line with NICE’s estimates that 700 adults per year would be eligible for treatment as a result of its guidance.</p><p>However, NHS England has further advised that it is more than willing to receive and review by the end of July, any further evidence that patients and clinicians wish to submit on this matter. The evidence will first be considered by NHS England’s Chemotherapy CRG, with advice and recommendations from this group then being submitted to the National Medical Director, Professor Steve Powis, for consideration.</p><p>During 2017/18, 1,193 Individual Funding Requests were considered by NHS England. An analysis of how may related to treatments for blood cancer has not been conducted.</p><p> </p>
star this property answering member printed Lord O'Shaughnessy more like this
star this property grouped question UIN
HL8561 more like this
HL8562 more like this
HL8563 more like this
star this property question first answered
less than 2018-06-26T12:13:53.757Zmore like thismore than 2018-06-26T12:13:53.757Z
star this property answering member
4545
star this property label Biography information for Lord O'Shaughnessy more like this
star this property tabling member
4286
unstar this property label Biography information for Lord Mendelsohn more like this
922989
star this property registered interest false more like this
star this property date less than 2018-06-12more like thismore than 2018-06-12
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
star this property hansard heading NHS: Drugs more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government how NHS England formulates approval criteria for drugs already approved by the National Institute for Health and Clinical Excellence; and how it involves (1) patients, and (2) clinicians in this process. more like this
star this property tabling member printed
Lord Mendelsohn remove filter
star this property uin HL8562 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2018-06-26more like thismore than 2018-06-26
unstar this property answer text <p>NHS England has advised that it develops treatment criteria for cancer and other high cost drugs to support implementation of National Institute for Health and Care Excellence (NICE) guidance and to ensure approved treatments are available as intended, with access funded consistently across the country. These criteria are developed by relevant expert clinical advisers, drawn from NHS England’s 42 Clinical Reference Groups (CRGs). These CRGs have been established to support clinical commissioning across the entire specialised commissioning portfolio.</p><p>In the case of NICE Technology Appraisal TA429 for ibrutinib in previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation, NICE issued the following statement on 8 June 2018:</p><p><strong> </strong>“Given the evidence that was considered by the NICE appraisal committee, we consider it reasonable for the guidance to be read as referring to those patients considered unsuitable for retreatment. Because unsuitability for retreatment is not defined in the guidance, we consider it appropriate for NHS England, as the commissioner, to take clinical advice in order to do so.”</p><p>NHS England took clinical advice in setting the specific treatment criteria linked to this appraisal and we are advised that the criteria were derived from the main study that had underpinned the NICE guidance and are consistent with guidance issued by the European Society for Medical Oncology last updated in June 2017. Between January 2017 and May 2018, nearly 1,000 patients were registered to receive treatment with ibrutinib in this indication. This is in line with NICE’s estimates that 700 adults per year would be eligible for treatment as a result of its guidance.</p><p>However, NHS England has further advised that it is more than willing to receive and review by the end of July, any further evidence that patients and clinicians wish to submit on this matter. The evidence will first be considered by NHS England’s Chemotherapy CRG, with advice and recommendations from this group then being submitted to the National Medical Director, Professor Steve Powis, for consideration.</p><p>During 2017/18, 1,193 Individual Funding Requests were considered by NHS England. An analysis of how may related to treatments for blood cancer has not been conducted.</p><p> </p>
star this property answering member printed Lord O'Shaughnessy more like this
star this property grouped question UIN
HL8561 more like this
HL8563 more like this
HL8564 more like this
star this property question first answered
less than 2018-06-26T12:13:53.617Zmore like thismore than 2018-06-26T12:13:53.617Z
star this property answering member
4545
star this property label Biography information for Lord O'Shaughnessy more like this
star this property tabling member
4286
unstar this property label Biography information for Lord Mendelsohn more like this
922990
star this property registered interest false more like this
star this property date less than 2018-06-12more like thismore than 2018-06-12
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
star this property hansard heading Haematological Cancer more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government how many Individual Funding Requests have been submitted to the NHS for the treatment of blood cancer; and of those, how many requests were (1) successful, and (2) unsuccessful. more like this
star this property tabling member printed
Lord Mendelsohn remove filter
star this property uin HL8563 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2018-06-26more like thismore than 2018-06-26
unstar this property answer text <p>NHS England has advised that it develops treatment criteria for cancer and other high cost drugs to support implementation of National Institute for Health and Care Excellence (NICE) guidance and to ensure approved treatments are available as intended, with access funded consistently across the country. These criteria are developed by relevant expert clinical advisers, drawn from NHS England’s 42 Clinical Reference Groups (CRGs). These CRGs have been established to support clinical commissioning across the entire specialised commissioning portfolio.</p><p>In the case of NICE Technology Appraisal TA429 for ibrutinib in previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation, NICE issued the following statement on 8 June 2018:</p><p><strong> </strong>“Given the evidence that was considered by the NICE appraisal committee, we consider it reasonable for the guidance to be read as referring to those patients considered unsuitable for retreatment. Because unsuitability for retreatment is not defined in the guidance, we consider it appropriate for NHS England, as the commissioner, to take clinical advice in order to do so.”</p><p>NHS England took clinical advice in setting the specific treatment criteria linked to this appraisal and we are advised that the criteria were derived from the main study that had underpinned the NICE guidance and are consistent with guidance issued by the European Society for Medical Oncology last updated in June 2017. Between January 2017 and May 2018, nearly 1,000 patients were registered to receive treatment with ibrutinib in this indication. This is in line with NICE’s estimates that 700 adults per year would be eligible for treatment as a result of its guidance.</p><p>However, NHS England has further advised that it is more than willing to receive and review by the end of July, any further evidence that patients and clinicians wish to submit on this matter. The evidence will first be considered by NHS England’s Chemotherapy CRG, with advice and recommendations from this group then being submitted to the National Medical Director, Professor Steve Powis, for consideration.</p><p>During 2017/18, 1,193 Individual Funding Requests were considered by NHS England. An analysis of how may related to treatments for blood cancer has not been conducted.</p><p> </p>
star this property answering member printed Lord O'Shaughnessy more like this
star this property grouped question UIN
HL8561 more like this
HL8562 more like this
HL8564 more like this
star this property question first answered
less than 2018-06-26T12:13:53.693Zmore like thismore than 2018-06-26T12:13:53.693Z
star this property answering member
4545
star this property label Biography information for Lord O'Shaughnessy more like this
star this property tabling member
4286
unstar this property label Biography information for Lord Mendelsohn more like this
940091
star this property registered interest false more like this
star this property date less than 2018-07-12more like thismore than 2018-07-12
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
star this property hansard heading Medical Treatments more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government how they review treatment criteria; and in how many cases treatment criteria have been amended since their implementation. more like this
star this property tabling member printed
Lord Mendelsohn remove filter
star this property uin HL9506 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2018-07-25more like thismore than 2018-07-25
unstar this property answer text <p>NHS England is responsible for the processes it uses to translate recommendations by the National Institute for Health and Care Excellence (NICE) into its treatment criteria. NHS England’s treatment criteria are under constant review and are amended as appropriate to reflect feedback from stakeholders including clinicians, companies, licensing agencies and NICE and to reflect changes to NHS England policies. Given that its treatment criteria are reviewed on an ongoing basis, NHS England is unable to provide the number of cases where the treatment criteria have been amended since their implementation.</p> more like this
star this property answering member printed Lord O'Shaughnessy more like this
star this property question first answered
less than 2018-07-25T11:05:14.103Zmore like thismore than 2018-07-25T11:05:14.103Z
star this property answering member
4545
star this property label Biography information for Lord O'Shaughnessy more like this
star this property tabling member
4286
unstar this property label Biography information for Lord Mendelsohn more like this
1005631
star this property registered interest false more like this
star this property date less than 2018-11-12more like thismore than 2018-11-12
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
star this property hansard heading Haematological Cancer more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what assessment they have made of the level of spending on treatment for and research into blood cancer in other countries compared to the UK. more like this
star this property tabling member printed
Lord Mendelsohn remove filter
star this property uin HL11402 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2018-11-26more like thismore than 2018-11-26
unstar this property answer text <p>NHS England does not hold information on the level of spending on blood cancer treatment in other countries.</p> more like this
star this property answering member printed Lord O'Shaughnessy more like this
star this property question first answered
less than 2018-11-26T13:00:38.673Zmore like thismore than 2018-11-26T13:00:38.673Z
star this property answering member
4545
star this property label Biography information for Lord O'Shaughnessy more like this
star this property tabling member
4286
unstar this property label Biography information for Lord Mendelsohn more like this
922992
star this property registered interest false more like this
star this property date less than 2018-06-12more like thismore than 2018-06-12
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
star this property hansard heading Cancer: Clinical Reference Groups more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what assessment they have made of the transparency of the decision-making process of NHS England in relation to cancer clinical reference groups and the frequency with which such groups meet. more like this
star this property tabling member printed
Lord Mendelsohn remove filter
star this property uin HL8565 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2018-06-26more like thismore than 2018-06-26
unstar this property answer text <p>NHS England’s current model of Clinical Reference Groups (CRG) was established following an extensive public engagement process which was completed during April 2016.</p><p>Since April 2016, the Cancer National Programme of Care has been supported by five CRGs (Chemotherapy, Radiotherapy, Specialised Cancer Surgery, Specialised Cancer Diagnostics and Children’s and Young People’s Cancer Services). The role of each CRG is to provide the primary source of clinical advice and leadership to NHS England on those services that are nationally commissioned. Each CRG comprises clinicians, patient and public voice representatives, professional association representation, public health experts and a commissioner and will usually meet between two and four times per year.</p><p>Transparency of decision making is important to NHS England. As a result, both stakeholder testing and public consultation are conducted regularly, in accordance with NHS England’s published Service Development Policy and Methods, in relation to the development of new clinical commissioning policy and service specifications.</p>
star this property answering member printed Lord O'Shaughnessy more like this
star this property question first answered
less than 2018-06-26T12:17:33.777Zmore like thismore than 2018-06-26T12:17:33.777Z
star this property answering member
4545
star this property label Biography information for Lord O'Shaughnessy more like this
star this property tabling member
4286
unstar this property label Biography information for Lord Mendelsohn more like this
916588
star this property registered interest false more like this
star this property date less than 2018-06-04more like thismore than 2018-06-04
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
star this property hansard heading Leukaemia: Ibrutinib more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what estimate NHS England has made of the number of people with relapsed or refractory chronic lymphocytic leukaemia who will not receive ibrutinib as a result of the treatment’s Blueteq Approval Criteria published on the National Cancer Drugs Fund List. more like this
star this property tabling member printed
Lord Mendelsohn remove filter
star this property uin HL8294 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2018-06-12more like thismore than 2018-06-12
unstar this property answer text <p>An estimate of the number of patients with chronic lymphocytic leukaemia who will not receive treatment is not available. NHS England has advised that 828 patients with chronic lymphocytic leukaemia were registered to receive ibrutinib in 2017/18.</p> more like this
star this property answering member printed Lord O'Shaughnessy more like this
star this property question first answered
less than 2018-06-12T10:51:00.643Zmore like thismore than 2018-06-12T10:51:00.643Z
star this property answering member
4545
star this property label Biography information for Lord O'Shaughnessy more like this
star this property tabling member
4286
unstar this property label Biography information for Lord Mendelsohn more like this
993366
star this property registered interest false more like this
star this property date less than 2018-10-22more like thismore than 2018-10-22
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
star this property hansard heading Haematological Cancer: Drugs more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what is the current level of spending by the NHS on blood cancer treatment; and what estimate they have made of the proportion of the NHS budget that will be spent on blood cancer treatments in each of the next five years. more like this
star this property tabling member printed
Lord Mendelsohn remove filter
star this property uin HL10894 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2018-11-05more like thismore than 2018-11-05
unstar this property answer text <p>NHS England is unable to provide current or previous spend on drugs specifically for blood cancer as many of these drugs have multiple indications. For the same reason it is not possible to estimate future spend.</p> more like this
star this property answering member printed Lord O'Shaughnessy more like this
star this property question first answered
less than 2018-11-05T13:36:52.667Zmore like thismore than 2018-11-05T13:36:52.667Z
star this property answering member
4545
star this property label Biography information for Lord O'Shaughnessy more like this
star this property tabling member
4286
unstar this property label Biography information for Lord Mendelsohn more like this
993367
star this property registered interest false more like this
star this property date less than 2018-10-22more like thismore than 2018-10-22
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
star this property hansard heading Medical Treatments more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what plans they have to consult on proposals to incorporate input from NHS England into the NICE technology appraisal process when determining treatment criteria. more like this
star this property tabling member printed
Lord Mendelsohn remove filter
star this property uin HL10895 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2018-11-05more like thismore than 2018-11-05
unstar this property answer text <p>The National Institute for Health and Care Excellence (NICE) is an independent body and is responsible for determining the processes it uses in the development of its guidance.</p><p>NICE has advised that it has no plans to consult on changes to its processes as it has been able to use its existing structures to ensure NHS England’s intended commissioning criteria are included within the appraisal process. NICE’s existing technology appraisal process that was updated in April 2018 already allows input from NHS England at various points.</p><p>Patient groups that are registered stakeholders participating in each technology appraisal will be able to provide their views on NHS England’s proposed commissioning criteria as part of the technical engagement step. Where applicable, all patient groups and individual patients have the opportunity to comment during consultation on an appraisal consultation document.</p> more like this
star this property answering member printed Lord O'Shaughnessy more like this
star this property grouped question UIN HL10896 more like this
star this property question first answered
less than 2018-11-05T15:13:35.9Zmore like thismore than 2018-11-05T15:13:35.9Z
star this property answering member
4545
star this property label Biography information for Lord O'Shaughnessy more like this
star this property tabling member
4286
unstar this property label Biography information for Lord Mendelsohn more like this